The concept of innovative drugs rose sharply and then fell back, and AstraZeneca approached its trading limit.

The concept of innovative drugs rose sharply intraday and then continued to fall, with high-level stocks such as Anglikon approaching the limit down. Shares of Nanxin Pharmaceuticals, Huasen Pharmaceuticals, Yuekang Pharmaceutical, Chenxin Pharmaceuticals, Guizhou Bailin, and Shutaishen all fell by more than 6%.